📊 PODD Key Takeaways
Is Insulet Corp. (PODD) a Good Investment?
Insulet demonstrates strong revenue growth of 30.7% and exceptional gross margins of 71.6%, indicating robust demand for its products and pricing power in the medical device sector. While net income declined 40.9% YoY, the company maintains excellent liquidity (2.81x current ratio), strong free cash flow of $377.7M, and conservative leverage (0.61x debt/equity), suggesting the profitability decline is likely due to growth-stage investments rather than fundamental deterioration.
Why Buy Insulet Corp. Stock? PODD Key Strengths
- Strong revenue growth of 30.7% YoY in medical device sector
- Exceptional gross margin of 71.6% indicating product quality and pricing power
- Robust free cash flow of $377.7M with 13.9% FCF margin demonstrating operational strength
- Excellent liquidity position with 2.81x current ratio and $716.1M cash
- Conservative leverage at 0.61x debt/equity with exceptional 44.3x interest coverage
- Solid ROE of 16.3% despite profitability headwinds
PODD Stock Risks: Insulet Corp. Investment Risks
- Net income declined 40.9% YoY despite revenue growth indicating margin compression and profitability concerns
- Diluted EPS fell 39.8% YoY, reflecting significant shareholder value deterioration
- Operating margin of only 17.5% with substantial expense burden between operating and net income
- Long-term debt of $930.8M represents material leverage that could constrain future flexibility
- Sustainability of 30.7% revenue growth unclear without visibility into market dynamics and competition
Key Metrics to Watch
- Net income trend and recovery path - profitability must stabilize or improve
- Operating margin stability - monitor for further compression below 17.5%
- Free cash flow conversion and sustainability amid profitability pressures
- Debt trajectory - ensure leverage remains controlled during growth phase
- Revenue growth sustainability - validate the 30.7% growth is repeatable and not cyclical
Insulet Corp. (PODD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.81x current ratio provides a solid financial cushion.
PODD Profit Margin, ROE & Profitability Analysis
PODD vs Healthcare Sector: How Insulet Corp. Compares
How Insulet Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Insulet Corp. Stock Overvalued? PODD Valuation Analysis 2026
Based on fundamental analysis, Insulet Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Insulet Corp. Balance Sheet: PODD Debt, Cash & Liquidity
PODD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Insulet Corp.'s revenue has grown significantly by 87% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.94 reflects profitable operations.
PODD Revenue Growth, EPS Growth & YoY Performance
PODD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $543.9M | $77.5M | $1.08 |
| Q2 2025 | $488.5M | $22.5M | $0.32 |
| Q1 2025 | $441.7M | $35.4M | $0.50 |
| Q3 2024 | $432.7M | $51.9M | $0.74 |
| Q2 2024 | $396.5M | $27.3M | $0.39 |
| Q1 2024 | $358.1M | $23.8M | $0.34 |
| Q3 2023 | $340.8M | -$5.2M | $-0.08 |
| Q2 2023 | $299.4M | -$7.2M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Insulet Corp. Dividends, Buybacks & Capital Allocation
PODD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Insulet Corp. (CIK: 0001145197)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PODD
What is the AI rating for PODD?
Insulet Corp. (PODD) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PODD's key strengths?
Claude: Strong revenue growth of 30.7% YoY in medical device sector. Exceptional gross margin of 71.6% indicating product quality and pricing power.
What are the risks of investing in PODD?
Claude: Net income declined 40.9% YoY despite revenue growth indicating margin compression and profitability concerns. Diluted EPS fell 39.8% YoY, reflecting significant shareholder value deterioration.
What is PODD's revenue and growth?
Insulet Corp. reported revenue of $2.7B.
Does PODD pay dividends?
Insulet Corp. does not currently pay dividends.
Where can I find PODD SEC filings?
Official SEC filings for Insulet Corp. (CIK: 0001145197) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PODD's EPS?
Insulet Corp. has a diluted EPS of $3.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PODD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Insulet Corp. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is PODD stock overvalued or undervalued?
Valuation metrics for PODD: ROE of 16.3% (sector avg: 15%), net margin of 9.1% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy PODD stock in 2026?
Our dual AI analysis gives Insulet Corp. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PODD's free cash flow?
Insulet Corp.'s operating cash flow is $569.3M, with capital expenditures of $191.6M. FCF margin is 13.9%.
How does PODD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 9.1% (avg: 12%), ROE 16.3% (avg: 15%), current ratio 2.81 (avg: 2).